Artificial intelligence prediction of therapy response in newly diagnosed adult severe primary immune
Xiaolin Zhai1,2, Saibing Qi1,2, Xiyan Wang1,2
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Background:
Newly diagnosed severe primary immune thrombocytopenia (ITP) with a platelet count of ≤10 × 109/L and clinically important bleeding requiring treatment is a medical emergency.
Objectives:
Using early kinetics of complete blood counts (CBC) to predict time interval to confirmed response in newly diagnosed severe primary ITP in adults.
Methods:
We used a training cohort of 85 adults with newly diagnosed severe primary ITP to develop an artificial intelligence model predicting confirmed response. The model used CBC values over the initial 5 days of therapy to classify subjects into 3 strata: high-confidence fast response, lower-confidence fast response, and slow/no response. We validated the model in an independent cohort of 59 subjects.
Results:
Concordance between the model-computed risk stratification and time to confirmed response is 0.78 (95% CI, 0.73, 0.82) and 0.78 (95% CI, 0.72, 0.83) in the training and validation cohorts, respectively. SHapley Additive exPlanations analyses indicated that the most informative covariates are age and kinetics of platelet count, mean red blood cell (RBC) volume, immature platelet fraction, standard deviation of RBC distribution width, mean RBC hemoglobin concentration, and immature reticulocyte percentage during days 3-5 of therapy.
Conclusion:
Our study should be treated as hypothesis-generating. Early dynamic patterns of CBC values might be used by artificial intelligence to predict the likelihood and speed of reaching confirmed response in adults with newly diagnosed severe primary ITP and might assist decision on timely therapy adjustment. Prospective testing and independent validation in non-Chinese cohorts and cohorts treated with different paradigms are needed.
